What started as a stuffy-nose and mild cold symptoms for 15-year-old Parker Turchan led to a far more serious diagnosis: a rare type of tumor in his nose and sinuses that extended through his skull near his brain. “He had always been a healthy kid, so we never imagined he had a tumor,” said Parker’s father, Karl. “We didn’t even know you could get a tumor in the back of your nose.”
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin, finds new research in mice led by UCL, Memorial Sloan Kettering (MSK) Cancer Center in New York and the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona.
Imaging research is one step closer to giving clinicians a way to do high-resolution scans of malignant cells in order to diagnose cancer and help identify useful therapies. If this technology were to prove successful in clinical studies, it might change how anatomic pathologists and radiologists diagnose and treat cancer.
Researchers have found that a combination of chemotherapy and modern radiotherapy can benefit patients with advanced nasopharyngeal cancer – a cancer that starts at the back of the nose. These cancers are very rare in the UK and so modern treatments had not been previously studied in patients with advanced disease.
Head and neck cancer patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells, as research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection. The study from the Universities of Birmingham and Warwick and University Hospitals Coventry and Warwickshire used advanced imaging to identify…
Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.
Randox Quality Control are pleased to announce, as part of our ongoing growth and development, the launch of our new Acusera Calibration Verification range for Beckman and Roche Cobas instruments.
Andrea G. Rockall, Consultant Radiologist at the Royal Marsden Hospital and Visiting Professor of Radiology at Imperial College in London, delivered the prestigious Wilhelm Conrad Röntgen Honorary Lecture at ECR 2016 on ‘Imaging the invisible killer: towards personalisation of ovarian cancer care’.
Results from recent trials are promising: an almost 40% increased breast cancer detection rate from digital breast tomosynthesis (DBT) screening compared to conventional mammography.
Scientists at the German Cancer Research Center (DKFZ) and the Stem Cell Institute HI-STEM in Heidelberg have discovered the reason why some pancreatic tumors are so resistant to treatment. They have found that these tumor cells produce larger quantities of an enzyme that usually occurs in the liver and degrades many drugs. If this enzyme is blocked, the cancer cells become sensitive towards…
Researchers have found the “bad seeds” of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new study has found.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Tumours kill off surrounding cells to make room to grow, according to new research from the University of Cambridge. Although the study was carried out using fruit flies, its findings suggest that drugs to prevent, rather than encourage, cell death might be effective at fighting cancer – contrary to how many of the current chemotherapy drugs work.
There’s apparently safety in numbers, even for cancer cells. New research in mice suggests that cancer cells rarely form metastatic tumors on their own, preferring to travel in groups since collaboration seems to increase their collective chances of survival, according to researchers at Johns Hopkins.
Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer.
When cells die, they don't vanish without a trace. Instead, they leave behind their fingerprints in the form of cell-free DNA. In people, these tiny fragments of DNA can be found in the bloodstream.
Healthcare, the world’s largest industry, is more than three times the size and value of the financial services sector, and is transforming faster than ever before, driving humanity to rethink the way we approach our health.
Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon’s ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology (MIT) and Lumicell Inc.
You’ve probably never heard of “sphingolipids” before. But these curiously named organic compounds play a vital role in one of humanity’s most well-known diseases: cancer.
Harms of screening are certain, but benefits in overall mortality are not … “We must be honest about this uncertainty,” experts say. Cancer screening has never been shown to “save lives” as advocates claim, argue experts in The BMJ.
Mom’s eyes and dad’s tumor? Cancer is due to genetic defects, some of which can be hereditary. The gene variant rs351855, for example, occurs in one in two cancer patients. A team headed by Axel Ullrich from the Max Planck Institute of Biochemistry in Martinsried identified the gene variant a decade ago. Now, they succeeded for the first time in showing that the variation exposes an otherwise…
A leading cause of cancer deaths worldwide, colon cancer is famously resistant to treatment. There are many reasons for this, but one has to do with a group of persisting cancer cells in the colon that cause relapses. Conventional therapies against them are mostly ineffective. EPFL scientists have now identified a biological mechanism that can be exploited to counteract colon cancer relapses.
Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.
As new scientific discoveries deepen our understanding of how cancer develops in children, doctors and other healthcare providers face challenges in better using that knowledge to guide treatment and counsel families and patients. In addition, as more children continue to survive pediatric cancer, that counseling may extend into a patient’s adulthood and old age.
A new injectable “biogel” is effective in delivering anti-cancer agents directly into cancerous tumours and killing them. This technology, developed by researchers at the University of Montreal Hospital Research Centre (CRCHUM), has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer.
